The molecular landscape of premenopausal breast cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Breast cancer in premenopausal women (preM) is frequently associated with worse prognosis compared to that in postmenopausal women (postM), and there is evidence that preM estrogen receptor-positive (ER+) tumors may respond poorly to endocrine therapy. There is, however, a paucity of studies characterizing molecular alterations in premenopausal tumors, a potential avenue for personalizing therapy for this group of women. METHODS: Using TCGA and METABRIC databases, we analyzed gene expression, copy number, methylation, somatic mutation, and reverse-phase protein array data in breast cancers from >2,500 preM and postM women. RESULTS: PreM tumors showed unique gene expression compared to postM tumors, however, this difference was limited to ER+ tumors. ER+ preM tumors showed unique DNA methylation, copy number and somatic mutations. Integrative pathway analysis revealed that preM tumors had elevated integrin/laminin and EGFR signaling, with enrichment for upstream TGFβ-regulation. Finally, preM tumors showed three different gene expression clusters with significantly different outcomes. CONCLUSION: Together these data suggest that ER+ preM tumors have distinct molecular characteristics compared to ER+ postM tumors, particularly with respect to integrin/laminin and EGFR signaling, which may represent therapeutic targets in this subgroup of breast cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon
Issa, J.-P. J., Ottaviano, Y. L., Celano, P., Hamilton, S. R., Davidson, N. E., & Baylin, S. B. (1994) · Nature Genetics · doi:10.1038/ng0894-536 · Cited by 1,191 · cited 1×
“Intriguingly, one report has shown increased ESR1 promoter methylation in colon cancer, as a function of age [26].”
BackgroundSelf-citationVaske, C. J., Benz, S. C., Sanborn, J. Z., Earl, D., Szeto, C., Zhu, J., Haussler, D., & Stuart, J. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq182 · Cited by 786 · cited 11×
“SL, RJH, SL, TM, and UC performed analyses of TCGA and METABRIC data, SB carried out integrated analysis using PARADIGM, and FM participated in ESR1 methylation analysis.”
MethodInfluentialSelf-citationA framework for feature selection in clustering
Witten, D. M., & Tibshirani, R. (2010) · Journal of the American Statistical Association · doi:10.1198/jasa.2010.tm09415 · Cited by 696 · cited 1×
“We further applied sparse k-means [17] clustering using R package sparcl.”
MethodGit, A., Dvinge, H., Salmon-Divon, M., Osborne, M., Kutter, C., Hadfield, J., Bertone, P., & Caldas, C. (2010) · RNA · doi:10.1261/rna.1947110 · Cited by 689
Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5579 · Cited by 499
Cited by
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025
Overall survival with ribociclib plus endocrine therapy in breast cancer
Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903765 · Cited by 1,001
MULTI-seq: sample multiplexing for single-cell RNA sequencing using lipid-tagged indices
McGinnis, C. S., Patterson, D. M., Winkler, J., Conrad, D. N., Hein, M. Y., Srivastava, V., Hu, J. L., Murrow, L. M., Weissman, J. S., Werb, Z., et al. (2019) · Nature Methods · doi:10.1038/s41592-019-0433-8 · Cited by 643
ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)
Paluch-Shimon, S., Cardoso, F., Partridge, A. H., Abulkhair, O., Azim, H. A., Bianchi-Micheli, G., Cardoso, M.-J., Curigliano, G., Gelmon, K. A., Harbeck, N., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.284 · Cited by 254
Metadata
- Authors
- Liao, S., Hartmaier, R. J., McGuire, K. P., Puhalla, S. L., Luthra, S., Chandran, U. R., Ma, T., Bhargava, R., Modugno, F., Davidson, N. E., Benz, S., Lee, A. V., Tseng, G. C., & Oesterreich, S.
- Venue
- Breast Cancer Research
- Published
- 2015-08-07
- Volume
- 17
- Issue
- 1
- Pages
- 104-104
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W1902218750
- Cited by
- 91
- References
- 6
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The molecular landscape of premenopausal breast cancer. https://app.cochat.ai/papers/10.1186/s13058-015-0618-8
- The paper
- Liao, S., Hartmaier, R. J., McGuire, K. P., Puhalla, S. L., Luthra, S., Chandran, U. R., Ma, T., Bhargava, R., Modugno, F., Davidson, N. E., Benz, S., Lee, A. V., Tseng, G. C., & Oesterreich, S. (2015). The molecular landscape of premenopausal breast cancer. Breast Cancer Research. https://doi.org/10.1186/s13058-015-0618-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.